Protara Therapeutics, Inc. (TARA) › Shareholders' EquityProtara Therapeutics, Inc. (TARA) — Shareholders' EquityAnnual figures by period end, from SEC filings.2011-12-31: -$72.66M2012-12-31: -$86.66M2013-12-31: -$100.51M2014-12-31: $82.46M2015-12-31: $63.41M2016-12-31: $38.44M2017-12-31: $34.74M2018-12-31: $4.78M2019-12-31: -$2.13M2020-12-31: $199.24M2021-12-31: $161.91M2022-12-31: $102.08M2023-12-31: $68.32M2024-12-31: $167.13M2025-12-31: $196.41M$196.41M2011-12-31Shareholders' Equity (USD)2025-12-31Period endedShareholders' EquityChange YoYSource filing2025-12-31$196.41M+17.5%2026-03-10Balance as of period end2024-12-31$167.13M+144.6%2026-03-10Balance as of period end2023-12-31$68.32M-33.1%2026-03-10Balance as of period end2022-12-31$102.08M-37.0%2025-03-05Balance as of period end2021-12-31$161.91M-18.7%2024-03-13Balance as of period end2020-12-31$199.24M—2023-03-08Balance as of period end2019-12-31-$2.13M-144.5%2022-03-09Balance as of period end2018-12-31$4.78M-86.2%2021-03-11Balance as of period end2017-12-31$34.74M-9.6%2020-03-20Balance as of period end2016-12-31$38.44M-39.4%2019-03-13Balance as of period end2015-12-31$63.41M-23.1%2019-03-13Balance as of period end2014-12-31$82.46M—2018-03-14Balance as of period end2013-12-31-$100.51M—2017-03-16Balance as of period end2012-12-31-$86.66M—2016-03-14Balance as of period end2011-12-31-$72.66M—2015-03-20Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)